Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease

Authors:

Abstract
Human prion diseases are fatal neurodegenerative conditions, which may occur sporadically, be inherited by coding mutation in the prion protein gene (PRNP), or be acquired from iatrogenic or dietary exposure to prions.1 Approximately 90 to 120 people are diagnosed as having prion disease each year in the United Kingdom.2 Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common form (approximately 85%) and the most obvious target for clinical trials. Typically, sCJD manifests as a rapidly progressive dementia with myoclonus and other neurological signs. The median clinical duration is approximately 4 months, although forms with short (few weeks) and long (>2 years) durations are well recognized.3 The fundamental pathogenic process in prion disease is the conversion of host cellular prion protein (PrPC) to abnormally folded multimeric forms (PrPSc and other disease-related forms) by seeded polymerization, a process that is thought to be widely shared in neurodegeneration.4 Prion diseases are particularly tractable for drug development, with clear target validation and availability of suitable cellular and animal models. Indeed, laboratory animals are naturally susceptible to prion infections, providing increased confidence that therapeutics shown to be active in preclinical models may translate to humans. Passive immunotherapy with monoclonal antibodies targeting PrPC has been shown to be effective in mouse models,5 and humanized antibodies developed for clinical trial6 and small-molecule therapeutics, which suppress prion replication and delay or prevent disease progression in mice, have been reported from multiple laboratories.7-9 However, to our knowledge, there is no effective therapeutic that has been shown to modify the course of the human disease.

This publication has 27 references indexed in Scilit: